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Autoimmune Pancreatitis
Type 2: Case Report
Chidinma Onweni, MD1, Harika Balagoni, MD1,
Jennifer M. Treece, MD, MBA1, Emmanuel Addo Yobo, MD1,
Archi Patel, MD1, Jennifer Phemister, MD1,2,
Manoj Srinath, MD1,2, and Mark F. Young, MD1,2

Abstract
A middle-aged man presents with acute pancreatitis of unknown etiology and is found to have a presentation consistent with
the diagnosis of type 2 autoimmune pancreatitis (AIP). AIP is a group of rare heterogeneous diseases that are challenging
to diagnose. There are 2 types of AIP. Type 1 disease is the more common worldwide than type 2 AIP. While type 1
AIP is associated with IgG4-positive antibodies, type 2 AIP is IgG4 antibody negative. Both types of AIP are responsive to
corticosteroid treatment. Although type 1 AIP has more extrapancreatic manifestations and more commonly relapses, this
is a case of a patient with type 2 AIP with inflammatory bowel disease and relapsing course.
Keywords
autoimmune pancreatitis, type 1, type 2, corticosteroid therapy, IgG4 antibody, IgG4-related disease, chronic pancreatitis,
lymphoplasmacytic sclerosing pancreatitis

Case Report
We report a case of a 64-year-old male patient who presented with acute pancreatitis. The patient’s history of present illness, past medical history, recent social history, right
upper quadrant ultrasonography, and hepatitis panel were
all nonsuggestive of an etiology for the patient’s acute pancreatitis. Of note, the patient admitted to a remote smoking
history, remote heavy drinking as a teenager, and denied
illicit drug use. Magnetic resonance cholangiopancreatography showed dilated intrahepatic and extrahepatic bile
ducts and a distal common bile duct (CBD) stricture with a
moderately enlarged head of the pancreas. Laboratory studies collected during the hospital admission were negative
for anti-mitochondrial antibody, negative for anti-smooth
muscle antibody, negative for immunoglobulin G (IgG)
subclasses, antinuclear antibody (ANA) was negative, and
the hepatitis panel was also negative. The patient’s symptoms improved gradually, so the patient was discharged
home without a definitive diagnosis for the underlying etiology of his acute pancreatitis. A few days following hospital discharge home, the patient reported new onset of
persistent diarrhea. Initial fixed sigmoidoscopy showed circumferential lesion suggesting a diagnosis of ulcerative
colitis. A subsequent colonoscopy showed skipped lesions
suggesting a diagnosis of Crohn’s disease. The ileum was

not involved but rectum was involved. Because the patient’s
colon lesion and histological evaluation suggested both
ulcerative colitis and Crohn’s disease, the diagnosis of
indeterminate colitis was determined as neither was completely met (see Figure 1).
A few weeks later, he underwent an endoscopic ultrasound
(EUS), which showed a pancreatic head mass. Core biopsy of
the pancreatic mass revealed benign glandular cells, rare
mildly atypical ductal cells, few plasma cells, few inflammatory cells, and stains for immunoglobulin G4 (IgG4) and
CD138 demonstrated nonspecific staining, which were inconclusive. CD138 is known to be a plasma cell marker, but pancreatic acinar cells in chronic pancreatitis also express
CD138.1 Background debris with no malignant cells was also
identified. The patient was treated with intravenous (IV)
1

East Tennessee State University, Johnson City, TN, USA
James H. Quillen Veterans Affairs Medical Center, Mountain Home, TN,
USA
2

Received June 19, 2017. Revised August 16, 2017. Accepted September 4,
2017.
Corresponding Author:
Jennifer M. Treece, MD, Department of Internal Medicine, East Tennessee
State University, PO Box 70622, Johnson City, TN 37614, USA.
Email: treecejm@etsu.edu

Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License
(http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further
permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

2

Journal of Investigative Medicine High Impact Case Reports

Figure 1. Rectosigmoid colon, biopsy: Acute and chronic inflammation, cryptitis, crypt abscesses, crypt distortion, and crypt drop-out.
Focal surface ulceration is also noted on the colon biopsy, showing infiltrates consistent with colitis. No dysplasia identified.

corticosteroids with a slow taper of oral corticosteroids over
several months. After completing the corticosteroid course, a
repeated EUS was done approximately 6 months following
the first EUS, which was normal with no evidence of a dilated
CBD; the pancreatic head parenchyma appeared normal and
there was no evidence of a focal mass lesion or progression.
This implies that the patient’s pancreatitis was responsive to
corticosteroids, which indicates a diagnosis of an autoimmune cause.2 Type 2 AIP was diagnosed as this patient’s pancreatitis was IgG4 negative,2 associated with inflammatory
bowel disease,3 and is associated with mass in the head of the
pancreas,4 which was also present in this patient before treatment with corticosteroids.
Since his initial diagnosis of type 2 AIP, the patient has had
multiple recurrences of diarrhea and some recurrence pancreatitis following cessation of corticosteroid use. He was evaluated by multiple experts at several facilities, who recommended
focusing treatment on the patient’s indeterminate colitis with
immunomodulators. The patient was initially started on adalimumab (Humira) with improvement of colitis and control of
recurrent (one episode of recurrent) acute pancreatitis, which
allowed for tapering the patient off the chronic corticosteroids.
His diarrhea later returned, and he was found to have elevated
antibodies to adalimumab, so adalimumab was discontinued
and vedolizumab has been started, which is currently controlling the patient’s symptoms.

Epidemiology
Autoimmune pancreatitis is a group of rare heterogeneous
diseases. There are 2 types of AIP. Type 1 disease is the more
common worldwide than type 2 AIP.4 Type 1 AIP is more
common in men and occurs in patients that are approximately
60 years older, and type 2 AIP presents in patients that are 40
to 50 years old and occurs at the same frequency in males
and females.4

Pathology
Type 1 AIP is associated with elevated levels of IgG4positive cells and extrapancreatic manifestations.5 The histology of both type 1 and type 2 AIP includes periductal

lymphoplasmacytic infiltrate and storiform fibrosis, but type
2 also has granulocytic epithelial lesion duct change. The
pancreatic histology of type 1 AIP is known as lymphoplasmacytic sclerosing pancreatitis with obliterative phlebitis but
without predominant neutrophilic infiltrate in the lobule and
duct.2 In type 2 AIP, IgG4-positive cells are uncommon, IgG
is normal, predominant neutrophilic infiltrate in the lobule
and duct are present, and it is more difficult to diagnose than
Type 1 AIP7 (see Table 1).
The HISORt diagnostic criteria for diagnosing type 1 AIP
is shown in Table 2. HISORt stands for histology, pancreatic
imaging, serology, other organ involvement, and response to
therapy.9

Clinical Presentation and Diagnosis
Both types of AIP can present with obstructive jaundice and
weight loss. Type 2 AIP more commonly presents with
obstructive jaundice, abdominal pain, weight loss, and acute
pancreatitis.6 Patients with AIP present with chronic pancreatitis of unknown etiology. Extensive evaluation for underlying etiology of pancreatitis is indeterminate. AIP is seldom
encountered and is not a definitive diagnosis. Therefore,
some investigators have suggested using a combination of
laboratory testing, imaging, histological findings, association to other autoimmune disease, and response to corticosteroid treatment to establish the diagnosis.10 Type 1 AIP can be
diagnosed through imaging and serological markers positive
for IgG4 autoantibodies. Type 2 AIP requires core needle
biopsy to diagnose through localizing the granulocytic epithelial lesion of the pancreatic duct.4

Treatment
AIP is responsive to corticosteroid use in the acute setting, but
relapse is common following cessation of corticosteroid use.
Recurrence is more common in type 1 AIP but can occur in
type 2 AIP. Immunomodulators are effective in maintaining
remission.6 For the patient presented in this case, the patient
took repeated courses of corticosteroid with recurrence of
symptoms on cessation of corticosteroid treatment. An expert
at a prestigious university hospital recommended that the
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Table 1. Autoimmune Pancreatitis, Type 1 and Type 23-8.
Type 1

Type 2

4

4

Prevalence
Signs/symptoms

More common
Obstructive jaundice, weight loss7

Patient demographics

More common in men,4 mean age of presentation is
in sixth decade of life8
High7
Positive4
Many4

Serum IgG
IgG4 autoantibody
IgG4-positive plasma cells
Extrapancreatic manifestations
Imaging
Pancreatic histology

Differential diagnosis
Diagnosis
Treatment
Relapses
Prognosis

More common (50%)4
Sclerosing cholangitis7
Enlargement of the pancreas, diffuse or focal;
narrowing of the bile and pancreatic ducts4
Lymphoplasmacytic sclerosing pancreatitis, periductal
lymphoplasmacytic infiltrate, storiform fibrosis
(swirling pattern), obliterative phlebitis, and IgG4positive plasma cells5
Pancreatic ductal adenocarcinoma
Imaging and serological markers4
Corticosteroids and immunomodulators (eg,
rituximab)6
More common (35% to 60%)—needs
immunomodulators to maintain remission6
Good6

Less common
Obstructive jaundice, abdominal pain, weight
loss, acute pancreatitis6
Younger patients—present around 40-50
years old,4 equal between men and women
Normal7
Negative4
None or very few (<10 cells/high-power
field)4
Less common4
Associated with inflammatory bowel disease4
Mass of pancreatic head4
Granulocytic epithelial lesion duct change;
periductal lymphoplasmacytic infiltrate and
storiform fibrosis; predominant neutrophilic
infiltrate in the lobule and duct are present3
Pancreatic ductal adenocarcinoma
Core needle biopsy for histological
confirmation4
Corticosteroids and immunomodulators (eg,
rituximab)6
Less common (<10%)6
Good6

Table 2. The Mayo Clinic HISORt Criteria to Diagnose Type 1 AIP9.
Diagnostic Feature
Histology

Pancreatic Imaging

Serology
Other Organ involvement
Response to steroid therapy

Criteria
At least one of the following histological findings:
•• Periductal lymphoplasmacytic infiltrate with obliterative phlebitis and storiform fibrosis
•• Lymphoplasmacytic infiltrate with storiform fibrosis showing abundant (≥10 cells/high
power field) and IgG4-positive cells
•• Typical image:
•• Diffusely enlarged gland with delayed enhancement; diffusely irregular, attenuated main
pancreatic duct
•• Others:
•• Focal pancreatic mass/enlargement; focal pancreatic duct stricture; pancreatic calcification;
pancreatitis; or pancreatic atrophy
Elevated serum IgG4 level
Hilar/intrahepatic biliary strictures, persistent distal biliary stricture, parotid/lacrimal gland
involvement, mediastinal lymphadenopathy, retroperitoneal fibrosis
Resolution or marked improvement of pancreatic/extrapancreatic manifestations with steroid
therapy

patient’s treatment be directed toward colitis with biologic
therapy as it was thought that biologic may also provide benefit to AIP. The patient was started on Humira and was tapered
off prednisone. Six months later, the patient was experiencing
abdominal pain and diarrhea, stool studies were positive for
Clostridium difficile. At that time Humira drug levels and antibody levels were drawn, which showed elevated antibody levels. The patient completed a course of metronidazole with
resolution of symptoms. The patient was previously on

azathioprine but developed hepatotoxicity with liver function
tests and returned to normal after medication discontinuation.

Discussion
The purpose of this case report is to review the limited
knowledge that exists about AIP, particularly type 2 AIP,
which is rarer than type 1 AIP, and to discuss how AIP presents clinically with methods to diagnosis this elusive

4
disease. Type 1 AIP is the variant of AIP that has been
described and studied more extensively as it is more common than type 2 AIP.2 The current diagnostic criteria focus
on diagnosing type 1 AIP without assessing for type 2 AIP.
From this case, we learned that there is limited knowledge
about the diagnosis of type 2 AIP. The diagnosis is unclear
even following biopsy of the pancreas. As seen in this
patient, the biopsy of the pancreatic mass only revealed
benign glandular cells and background debris with no malignant cells identified. The diagnosis was presumed to be type
2 AIP due to IgG4 being negative, the patient responded to
corticosteroid treatment with improvement of symptoms,
and the resolution of the dilated intrahepatic and extrahepatic bile ducts, the distal CBD stricture, and the mass at the
head of the pancreas following corticosteroid use. Of note,
the sensitivity of serum IgG4 ranges from 53% to 95%, so
having a negative IgG4 level does not exclude type 1 AIP.11
It is interesting to note that type 1 AIP is associated with
biliary findings, primarily primary sclerosing cholangitis.
Type 2 AIP principally affects the pancreas, with only one
third having extrapancreatic magnifications, such as inflammatory bowel disease like ulcerative colitis. Our patient,
interestingly, fits into the one third of type 2 AIP cases with
extrapancreatic findings as he developed persistent diarrhea.
He was diagnosed with colitis, and the type of colitis was
unclear via biopsy. The gastroenterologist diagnosed him as
presumptive ulcerative colitis.

Conclusion
AIP is a rare disease with type 2 AIP being rarer than type 1
AIP. Diagnosing AIP is challenging as even a core needle
biopsy of a pancreatic mass is not useful in diagnosing AIP.2
AIP remains a rare disease and little is known about the diagnosis or underlying etiology, especially in type 2 AIP. Type 1
AIP has IgG4-positive antibodies. As relapse is very common following cessation of corticosteroid use treatment,
immunomodulators are needed to maintain remission for
both type 1 and type 2 AIP.
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